These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 21573890)

  • 1. Diffuse alveolar hemorrhage associated with lenalidomide.
    Sakai M; Kubota T; Kuwayama Y; Ikezoe T; Yokoyama A
    Int J Hematol; 2011 Jun; 93(6):830-831. PubMed ID: 21573890
    [No Abstract]   [Full Text] [Related]  

  • 2. Successful re-administration of lenalidomide after lenalidomide-induced pulmonary alveolar hemorrhage in a patient with refractory myeloma.
    Sakai M; Kubota T; Takaoka M; Tsukuda T; Arakawa Y; Anabuki K; Ikezoe T; Togitani K; Yokoyama A
    Ann Hematol; 2015 May; 94(5):891-2. PubMed ID: 25407112
    [No Abstract]   [Full Text] [Related]  

  • 3. Pulmonary alveolar hemorrhage possibly associated with lenalidomide use.
    Oshima Y; Tojo A
    Int J Hematol; 2011 Sep; 94(3):296-297. PubMed ID: 21858442
    [No Abstract]   [Full Text] [Related]  

  • 4. Lenalidomide-induced cytokine release syndrome in a patient with multiple myeloma.
    Nakamura N; Kanemura N; Shibata Y; Matsumoto T; Mabuchi R; Nakamura H; Kitagawa J; Goto N; Hara T; Tsurumi H; Moriwaki H
    Leuk Lymphoma; 2014 Jul; 55(7):1691-3. PubMed ID: 24138307
    [No Abstract]   [Full Text] [Related]  

  • 5. Cytokine profiles in relapsed multiple myeloma patients undergoing febrile reactions to lenalidomide.
    Morita Y; Shimada T; Yamaguchi T; Rai S; Hirase C; Emoto M; Serizawa K; Taniguchi Y; Ojima M; Tatsumi Y; Ashida T; Matsumura I
    Int J Hematol; 2011 Dec; 94(6):583-4. PubMed ID: 22127558
    [No Abstract]   [Full Text] [Related]  

  • 6. Acute lymphoblastic leukemia developing during maintenance therapy with lenalidomide in a patient with multiple myeloma.
    García-Muñoz R; Robles-de-Castro D; Muñoz-Rodríguez A; Rabasa P
    Leuk Lymphoma; 2013 Dec; 54(12):2753-5. PubMed ID: 23488662
    [No Abstract]   [Full Text] [Related]  

  • 7. Desensitization to lenalidomide in a patient with relapsed multiple myeloma.
    Seki JT; Banglawala S; Lentz EM; Reece DE
    Clin Lymphoma Myeloma Leuk; 2013 Apr; 13(2):162-5. PubMed ID: 23103087
    [No Abstract]   [Full Text] [Related]  

  • 8. Lenalidomide efficacy in bortezomib-resistant myeloma.
    Gozzetti A; Crupi R; Defina M; Bocchia M
    Nat Rev Clin Oncol; 2010 Sep; 7(9):. PubMed ID: 20824907
    [No Abstract]   [Full Text] [Related]  

  • 9. Lenalidomide induced intrahepatic cholestasis in newly diagnosed patients of multiple myeloma.
    Jena RK; Swain TR; Kansurkar SS; Swain M
    Eur J Clin Pharmacol; 2012 May; 68(5):881-4. PubMed ID: 22127618
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A case of severe aplastic anemia secondary to treatment with lenalidomide for multiple myeloma.
    Dasanu CA; Alexandrescu DT
    Eur J Haematol; 2009 Mar; 82(3):231-4. PubMed ID: 19018868
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Interstitial pneumonitis associated with the immunomodulatory drugs thalidomide and lenalidomide.
    Iino M
    Int J Hematol; 2012 Feb; 95(2):223-4. PubMed ID: 22198829
    [No Abstract]   [Full Text] [Related]  

  • 12. Fatal ischemic stroke in a patient receiving lenalidomide for multiple myeloma.
    Tannemaat MR; Vries EP; Molendijk WJ; Haan J
    Clin Neurol Neurosurg; 2011 Jul; 113(6):488-9. PubMed ID: 21315504
    [No Abstract]   [Full Text] [Related]  

  • 13. A practical guide to achieving and maintaining the best response to lenalidomide in multiple myeloma: roundtable proceedings.
    Stadtmauer EA; Lonial S; Vesole DH; Abonour R; Alsina M; Badros A; Comenzo R; Durie B; Giralt S; Hussein M; Jakubowiak A; Mehta J; Niesvizky R; Orlowski R; Siegel D; Singhal S; Vescio R; Wang M; Zangari M; Munshi NC
    Clin Adv Hematol Oncol; 2007 Oct; 5(10 Suppl 15):7-19, quiz 21-2. PubMed ID: 18000495
    [No Abstract]   [Full Text] [Related]  

  • 14. Lenalidomide, a thalidomide derivative, shows promise in various applications.
    Oestreicher P
    ONS Connect; 2007 Aug; 22(8):22-3. PubMed ID: 17824579
    [No Abstract]   [Full Text] [Related]  

  • 15. Lenalidomide for bortezomib-resistant multiple myeloma.
    Briani C; Berno T; Campagnolo M; Zambello R
    Nat Rev Clin Oncol; 2010 Sep; 7(9):. PubMed ID: 20824906
    [No Abstract]   [Full Text] [Related]  

  • 16. Lenalidomide: second cancers.
    Prescrire Int; 2012 May; 21(127):130. PubMed ID: 22844687
    [No Abstract]   [Full Text] [Related]  

  • 17. Lenalidomide and its role in the management of multiple myeloma.
    Falco P; Cavallo F; Larocca A; Liberati AM; Musto P; Boccadoro M; Palumbo A
    Expert Rev Anticancer Ther; 2008 Jun; 8(6):865-74. PubMed ID: 18533796
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [The use of lenalidomide in the treatment of multiple myeloma].
    Holánek M; Hájek R
    Klin Onkol; 2010; 23(2):67-72. PubMed ID: 20465083
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparative effectiveness and safety of thalidomide and lenalidomide in patients with multiple myeloma in the United States of America: A population-based cohort study.
    Luo J; Gagne JJ; Landon J; Avorn J; Kesselheim AS
    Eur J Cancer; 2017 Jan; 70():22-33. PubMed ID: 27866096
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The clinical utility of lenalidomide in multiple myeloma and myelodysplastic syndromes.
    Bonkowski J; Vermeulen LC; Kolesar JM
    J Oncol Pharm Pract; 2010 Dec; 16(4):223-32. PubMed ID: 19910392
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.